Go Back   ManagementParadise.com Discussion Forums PUBLISH / UPLOAD PROJECT OR DOWNLOAD REFERENCE PROJECT > Principles of Management ( P.O.M)

SWOT ANALYSIS ON International Medical Corporation

Discuss SWOT ANALYSIS ON International Medical Corporation within the Principles of Management ( P.O.M) forums, part of the PUBLISH / UPLOAD PROJECT OR DOWNLOAD REFERENCE PROJECT category; JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics ...

Reply

 

Thread Tools Display Modes
SWOT ANALYSIS ON International Medical Corporation
Old
 (1 (permalink))
Abhijeet S
abhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to beholdabhishreshthaa is a splendid one to behold
 
abhishreshthaa
Operations Manager at Management Paradise
Management Paradise Guru
 
Status: Offline
Posts: 7,045
Join Date: May 2010
SWOT ANALYSIS ON International Medical Corporation - November 30th, 2010

JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1997 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNI) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore. JNI partners with Global Health Organizations such as the Clinton Global Initiative,[1],the Global Business Coalition, New York[2] President's Malaria Initiative and PEPFAR.[3][4][5] JNI also partners with several other non-profit global health organizations,[6][7] NGOs, local governments and communities in developing countries to address the health issues related to HIV AIDS Malaria Tuberculosis and Bacterial Meningitis that scourges the underserved communities in West Africa, South East Asia and Latin America.


Strengths

* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise

Weaknesses

* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products

Opportunities

* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi

Threats

* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth
Advertisements



Help Others > Network > Grow


Work with us part time/full time as forum moderator. Email us your resume on careers @ managementparadise.com PLS PRESS THANKS BUTTON IF U LIKED MY POST.


To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts.
Friends: (0)
Reply With Quote
Re: SWOT ANALYSIS ON International Medical Corporation
Old
 (2 (permalink))
Jitendra Mazee
jitendra05 is on a distinguished road
 
jitendra05
Student of Bachelor of Engineering at RGTU Bhopal
Bhopal, Madhya Pradesh
Management Paradise Guru
 
Institute: RGTU Bhopal
Status: Offline
Posts: 27,841
Join Date: Jan 2016
Location: Bhopal, Madhya Pradesh
Re: SWOT ANALYSIS ON International Medical Corporation - 2 Weeks Ago

Quote:
Originally Posted by abhishreshthaa View Post
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1997 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNI) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore. JNI partners with Global Health Organizations such as the Clinton Global Initiative,[1],the Global Business Coalition, New York[2] President's Malaria Initiative and PEPFAR.[3][4][5] JNI also partners with several other non-profit global health organizations,[6][7] NGOs, local governments and communities in developing countries to address the health issues related to HIV AIDS Malaria Tuberculosis and Bacterial Meningitis that scourges the underserved communities in West Africa, South East Asia and Latin America.


Strengths

* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise

Weaknesses

* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products

Opportunities

* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi

Threats

* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth
Hey dear, i think you did a great job and your content on International Medical Corporation would help many people. BTW, i thought i should also add something so i am uploading a document which would give useful information on International Medical Corporation.
Attached Files
File Type: pdf International Medical Corporation.pdf (111.2 KB, 0 views)
Friends: (0)
Reply With Quote
Reply

Bookmarks

Tags
analysis, bad communication, brand equity, corporation, cost advantage, development labs, financial position, global experience, high r&d, high-quality, international, loyal customers, manufacturing base, market share, medical, pricing, process development, risk management, services expansion, strong brand, strong management, supply chain, swot, swot analysis, swot of us companies
Related to SWOT ANALYSIS ON International Medical Corporation
 

Similar Threads

Thread Thread Starter Forum Replies Last Post
SWOT ANALYSIS ON EMC Corporation Abhijeet S Principles of Management ( P.O.M) 1 2 Weeks Ago 05:47 PM
SWOT ANALYSIS ON Dex One Corporation Abhijeet S Principles of Management ( P.O.M) 1 2 Weeks Ago 05:27 PM
SWOT ANALYSIS ON BB&T Corporation Abhijeet S Principles of Management ( P.O.M) 1 2 Weeks Ago 02:56 PM
SWOT ANALYSIS ON AES Corporation Abhijeet S Principles of Management ( P.O.M) 1 4 Weeks Ago 01:19 PM
SWOT ANALYSIS ON KFC Corporation Abhijeet S Principles of Management ( P.O.M) 2 June 27th, 2015 05:57 PM
 


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On
Trackbacks are On
Pingbacks are On
Refbacks are Off


ManagementParadise.com is not responsible for the views and opinion of the posters. The posters and only posters shall be liable for any copyright infringement.



Search Engine Optimization by vBSEO ©2011, Crawlability, Inc.